Today Canada’s National Centre for Drug Research and Development announced a collaboration with Schrödinger Inc to use artificial intelligence to help facilitate the development of new therapeutic antibodies. “We’re excited to work with CDRD to aggressively translate scientific discoveries into innovative therapeutic products,” said Dr. Ramy Farid, Schrödinger’s President and CEO. “This partnership is an important step forward in our efforts to extend the successes we’ve had in small molecule drug discovery to the development of novel biologics.”